Sumeru Equity Partners acquired 100% of the share capital of beqom SA, a Swiss-based provider of employee compensation management and performance software solutions for large companies of various industry sectors.

Four startups in the life sciences and ICT sectors have recently restructured their leadership teams, appointing new CEOs, CTOs, and CFOs to propel their growth ambitions. Notably, Cytosurge and beqom have said goodbye to their long-serving leaders, marking the start of a new era in the companies after more than a decade.Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, is advancing a portfolio of transformative, first-in-disease therapeutics targeting neuroscience-based conditions with high unmet needs. Noema has four programs currently in active Phase 2 clinical trials evaluating seizures in Tuberous Sclerosis Complex, pain in Trigeminal Neuralgia, Tourette syndrome and vasomotor symptoms plus CNS-mediated symptoms of menopause with readouts expected in 2025. The company has strengthened its leadership team with the appointment of Michael Samar as Chief Financial Officer (CFO). Michael brings 25 years of experience in life sciences and biotech, serving as both a strategic partner and a financial advisor to growth-phase and impact-driven organizations while helping forge a culture of success. Leadership transition at Cytosurge Cytosurge AG, a biotech company pioneering innovative single-cell biopsies and cell-line engineering solutions, announces a leadership transition effective January 1, 2025